Skip to main
  1. Stocks
  2. Cogent Biosciences, Inc.
  3. Forecast
COGT

COGT Stock Forecast & Price Target

COGT Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Cogent Biosciences is supported by a strong bezuclastinib data package, with the APEX trial showing a 65% ORR in AdvSM, 81% response by pathological criteria, and durable 12-month PFS/OS of 79%/87%, which underpins confidence in regulatory approval. The company also has multiple near-term catalysts, including FDA PDUFA dates for GIST on November 30, 2026, NonAdvSM on December 30, 2026, and AdvSM on June 29, 2027, creating a potentially transformative commercial run-rate across three indications. Financially, it ended 3Q26 with $791.1M in cash and equivalents and a projected runway into late 2028, while the modest 3Q26 net loss of $0.59 per share suggests sufficient balance-sheet strength to execute its pipeline.

Bears say

Cogent Biosciences is viewed negatively because AdvSM remains a competitive market, with Sanofi’s Ayvakit already established as the standard of care and physicians having substantial experience with an effective KIT inhibitor, making utilization gains difficult without heavy commercial spending. The company’s valuation is especially vulnerable to poorer-than-expected clinical results from CGT9486, which could force lower market penetration assumptions, higher discount rates, and a longer path to approval or even prevent approval entirely. Additional downside comes from the risk of stronger competitor products and broader regulatory and commercial execution challenges, leaving the investment case dependent on overcoming significant clinical and adoption hurdles.

COGT has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Cogent Biosciences, Inc. and is not a guaranteed prediction by Public.com or investment advice.

COGT Analyst Forecast & Price Prediction

Get the latest COGT stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in COGT

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Cogent Biosciences, Inc. (COGT) Forecast

Analysts have given COGT a Buy based on their latest research and market trends.

According to 6 analysts, COGT has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $56.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $56.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Cogent Biosciences, Inc. (COGT)


COGT Analyst Forecast & Price Prediction

Get the latest COGT stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in COGT

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover COGT stock data and trends